Levetiracetam (All indications)

Cleft lip with or without cleft palate

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S10170
R37120		 Blotière (Levetiracetam) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019 Cleft lip with or without cleft palate 1st trimester retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: No 2.59 [0.23;28.62] C
excluded (control group) 		1/579   2/2,997 3 579
ref
S10037
R36205		 Blotière (Levetiracetam) (Controls unexposed NOS) (Mixed indications), 2019 Cleft lip with or without cleft palate 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 2.00 [0.10;11.10] 1/579   1,637/1,875,733 1,638 579
ref
S9829
R35233		 Vajda (Levetiracetam) (Controls unexposed, sick), 2013 Palate/lip malformation at least 1st trimester prospective cohort unexposed, sick Adjustment: No 2.34 [0.05;119.47] C 0/63   0/147 0 63
ref
Total 2 studies 2.09 [0.28;15.72] 1,638 642
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Blotière (Levetiracetam) (Controls unexposed NOS) (Mixed indications), 2019Blotière, 2019 1 2.00[0.10; 11.10]1,63857974%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Vajda (Levetiracetam) (Controls unexposed, sick), 2013Vajda, 2013 2 2.34[0.05; 119.47]06326%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 0% 2.09[0.28; 15.72]1,6386420.95.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Levetiracetam) (Controls unexposed NOS) (Mixed indications; 2: Levetiracetam) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 2.09[0.28; 15.72]1,6386420%NABlotière (Levetiracetam) (Controls unexposed NOS) (Mixed indications), 2019 Vajda (Levetiracetam) (Controls unexposed, sick), 2013 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 2.00[0.19; 21.07]1,638579 -NABlotière (Levetiracetam) (Controls unexposed NOS) (Mixed indications), 2019 1 unexposed, sickunexposed, sick 2.34[0.05; 119.47]-63 -NAVajda (Levetiracetam) (Controls unexposed, sick), 2013 1 Tags Adjustment   - No  - No 2.09[0.28; 15.72]1,6386420%NABlotière (Levetiracetam) (Controls unexposed NOS) (Mixed indications), 2019 Vajda (Levetiracetam) (Controls unexposed, sick), 2013 2 All studiesAll studies 2.09[0.28; 15.72]1,6386420%NABlotière (Levetiracetam) (Controls unexposed NOS) (Mixed indications), 2019 Vajda (Levetiracetam) (Controls unexposed, sick), 2013 20.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 10170

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 2.00[0.19; 21.07]1,638579 -NABlotière (Levetiracetam) (Controls unexposed NOS) (Mixed indications), 2019 1 unexposed, sick controlsunexposed, sick controls 2.34[0.05; 119.47]-63 -NAVajda (Levetiracetam) (Controls unexposed, sick), 2013 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 2.59[0.23; 28.62]3579 -NABlotière (Levetiracetam) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019 10.510.01.0